JAK1 and Alzheimer disease: Finally, a network meta-analysis compared the incidence and risk of herpes zoster among patients with moderate-to-severe AD treated with advanced systemic therapies and found that JAK1 inhibitors are associated with a significantly higher incidence compared to dupilumab and placebo [82].